Carregando...

Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors

In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Rilan BAI, Naifei CHEN, Jiuwei CUI
Formato: Artigo
Idioma:Chinês
Publicado em: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-08-01
coleção:Chinese Journal of Lung Cancer
Assuntos:
Acesso em linha:http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!